Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,856 active trials61 approved drugs307 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,398 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07059884 | Distance-Based Exercise to Preserve Function and Prevent Disability(DEFEND) | recruiting | N/A | 104 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07226544 | Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer | recruiting | Phase 2 | 31 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07444814 | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 226 | Whitehawk Therapeutics, Inc.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07684508 | Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Cervical Cancer | recruiting | N/A | 154 | Manni HuangOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07747272 | Nerve-SPARing Robotic Prostatectomy: The Impact of Patient Baseline Profiles on Erectile Function(SPARE-EF) | recruiting | — | 300 | University of FlorenceOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01) | recruiting | Phase 1 / Phase 2 | 884 | GenmabINDUSTRY | 3 | Aug 4, 2026 | clinicaltrials |
| NCT06076538 | PET/MR for Characterization of Renal Masses (RMs) | recruiting | — | 97 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06476184 | Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery(SALVOVAR) | recruiting | Phase 3 | 250 | ARCAGY/ GINECO GROUPOTHER | 4 | Aug 4, 2026 | clinicaltrials |
| NCT06960577 | Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) | recruiting | Phase 3 | 150 | AstraZenecaINDUSTRY | 7 | Aug 4, 2026 | clinicaltrials |
| NCT07364071 | Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer(SENTRY) | recruiting | Phase 2 | 150 | University of California, San DiegoOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07743749 | An MRI-Based Study of Intelligent Pathological Subtyping and Grading of Renal Tumors | recruiting | — | 900 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07743918 | Vitamin D Status and Clinical Outcomes in Locally Advanced Cervical Cancer(CERVITAL) | recruiting | — | 100 | University of KragujevacOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04934540 | The Global En Bloc Resection of Bladder Tumour Registry | recruiting | — | 2,000 | Chinese University of Hong KongOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05433142 | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 | 307 | Xencor, Inc.INDUSTRY | 5 | Aug 3, 2026 | clinicaltrials |
| NCT05603910 | Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma | recruiting | Phase 1 | 18 | Aaron WolfsonOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06096688 | Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction | recruiting | — | 1,120 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06124976 | Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma | recruiting | Phase 2 / Phase 3 | 70 | Peter BlackOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07225309 | A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer | recruiting | N/A | 300 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Aug 3, 2026 | clinicaltrials |
| NCT07227402 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)(LITESPARK-033) | recruiting | Phase 3 | 904 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Aug 3, 2026 | clinicaltrials |
| NCT07300241 | Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 | 30 | Neomorph, IncINDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07429071 | Effectiveness of a Vaginal Gel on CIN1/2 Regression and HPV Clearance. | recruiting | N/A | 70 | University of AarhusOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07611825 | Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma(REMEDY-RCC) | recruiting | Phase 2 | 33 | Jinling Hospital, ChinaOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07741435 | Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia(METHYLSCAPE-CO) | recruiting | — | 3,250 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07741929 | Patient and Provider Perspectives on Genetic Risk Profiling(PPP) | recruiting | — | 40 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05283421 | Improving Diagnostics in Cervical Dysplasia(IDEAL) | recruiting | N/A | 150 | University of AarhusOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05759923 | First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours | recruiting | Phase 1 | 40 | Molecure S.A.INDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06613100 | Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer | recruiting | Phase 1 | 40 | AmgenINDUSTRY | 2 | Jul 31, 2026 | clinicaltrials |
| NCT06625970 | Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse(PEACE 7) | recruiting | Phase 3 | 700 | UNICANCEROTHER | 2 | Jul 31, 2026 | clinicaltrials |
| NCT06866262 | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial | recruiting | Phase 1 / Phase 2 | 55 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06954337 | MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial | recruiting | N/A | 1,750 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07209917 | Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India(SAKHI) | recruiting | N/A | 348 | University of California, IrvineOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07225127 | Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2(CISTO2) | recruiting | — | 408 | University of WashingtonOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07281430 | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) | recruiting | N/A | 500 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | recruiting | Phase 1 | 70 | Compass TherapeuticsINDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07646847 | A Study of a Side Effects and Resource Navigation Program for People With Cancer | recruiting | N/A | 200 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07739121 | Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations(BEACON) | recruiting | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07740239 | A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial(COSMOS-I) | recruiting | — | 2,050 | Tampere University HospitalOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03877796 | Clinical Pre-screening Protocol for Ovarian Cancer | recruiting | — | 60 | Allarity TherapeuticsINDUSTRY | 2 | Jul 30, 2026 | clinicaltrials |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT04831580 | A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer(ROCC) | recruiting | N/A | 840 | GOG FoundationNETWORK | 4 | Jul 30, 2026 | clinicaltrials |
| NCT05663710 | Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC | recruiting | Phase 1 / Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05751434 | A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer | recruiting | Phase 2 | 102 | City of Hope Medical CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05765500 | RecoverPC: Relugolix vs GnRH Agonist in Quality of Life | recruiting | Phase 2 | 110 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06325046 | Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer | recruiting | N/A | 164 | Mayo ClinicOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06963346 | Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents | recruiting | Phase 1 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07179770 | Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC) | recruiting | Phase 1 | 12 | NYU Langone HealthOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07203482 | Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation | recruiting | — | 300 | NYU Langone HealthOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07288359 | Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 205 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 30, 2026 | clinicaltrials |
| NCT07634380 | Sitagliptin With Pembro in RCC and Melanoma | recruiting | Phase 1 | 64 | Fernando Maciel BarbosaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07730970 | Deep Neuromuscular Blockade and a Low-Residue Diet for the Surgical Field in vNOTES Hysterectomy(vNOTES_NMBDIET) | recruiting | N/A | 160 | Fatih Sultan Mehmet Training and Research HospitalOTHER | 1 | Jul 30, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Aug 5, 2026source: clinicaltrials